Abstract:Extracellular targeted protein degradation (eTPD) is an emerging modality to regulate protein levels without genomic interruption. Current strategies co-opt lysosome-targeting receptors (LTRs) that are ubiquitously present in most cells, offering a high success rate of eTPD across cell types and tissues. Opening up the binding complementarity requirement from LTRs to any overexpressed cell surface receptor offers to endow eTPD platforms with new cellular targeting capabilities. Here, we report polymeric lysosome-targeting chimeras (PolyTACs), a polymer-antibody conjugate based platform for the targeted degradation of membrane-bound and soluble proteins without the need for involving LTRs. Mechanistic investigations suggest a non-classical uptake pathway that is attributed to the membrane tension caused by the multivalent interaction between the PolyTACs and the overexpressed functionalities on the cell surface. The utility of PolyTACs in eTPD has been demonstrated with three therapeutically relevant membrane proteins. Additionally, the same design principle has also been leveraged to bind and drag soluble extracellular proteins into the lysosome. The design and fabrication simplicity, non-reliance on LTRs, and tissue-targeting capabilities open up new avenues for eTPD in many disease-specific applications.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an **extracellular targeted protein degradation (eTPD) technology that does not rely on lysosome - targeting receptors (LTRs)**. Specifically, the authors designed a new platform named **PolyTACs (polymeric lysosome - targeting chimeras)** for degrading membrane - bound proteins and soluble extracellular proteins without the need to use lysosome - targeting receptors that are ubiquitous in cells. ### Core problems: 1. **How to achieve extracellular protein degradation without relying on LTRs?** - Current extracellular protein degradation methods usually rely on lysosome - targeting receptors (such as mannose - 6 - phosphate receptor or asialoglycoprotein receptor). These receptors are ubiquitous in most cells but limit the ability to target specific cells or tissues. - This study proposes a PolyTAC platform based on polymer - antibody conjugates, which directly guides the target protein to the lysosome for degradation through multivalent interactions without relying on LTRs. 2. **How to improve the degradation efficiency of membrane proteins and soluble extracellular proteins?** - By designing PolyTACs, using antibodies to specifically bind to the target protein, and through multivalent interactions between the polymer and exofacial thiols overexpressed on the cell surface, endocytosis is induced and the target protein is transported to the lysosome. 3. **How to expand the application range of eTPD?** - In addition to degrading membrane proteins, PolyTACs can also bind to soluble extracellular proteins (such as VEGF, IgG) and transport them to the lysosome for degradation through a similar mechanism, thus providing a new strategy for treating cancer and autoimmune diseases. --- ### Core mechanisms of the solution: 1. **Design principle of PolyTAC**: - PolyTAC is composed of an antibody and a polymer. The antibody is responsible for specifically binding to the target protein, and the polymer binds to exofacial thiols overexpressed on the cell surface through multivalent interactions. - This multivalent interaction will cause changes in cell membrane tension, promote the occurrence of non - classical endocytosis pathways, and transport the target protein together with PolyTAC to the lysosome. 2. **Experimental verification**: - For membrane proteins (such as PD - L1, Trop2, EGFR) and soluble extracellular proteins (such as IgG, VEGF), it has been proven that PolyTACs can effectively degrade these proteins. - Using inhibitors (such as Bafilomycin A1), it has been verified that PolyTACs - mediated protein degradation depends on the lysosome pathway. - Studies have shown that multivalent interactions (especially the interaction between the polymer and cell - surface thiols) are the key driving factors. 3. **Advantages**: - It does not rely on LTRs, broadening the application range of eTPD in specific cells or tissues. - It has a simple design and is easy to synthesize and modify. - It can degrade multiple target proteins simultaneously and has potential clinical application value. --- ### Summary: The core problem of this paper is to develop an **extracellular targeted protein degradation technology that does not rely on LTRs** and verify its effectiveness in degrading membrane proteins and soluble extracellular proteins. By designing the PolyTACs platform, the authors have successfully achieved this goal and demonstrated its potential application prospects in cancer treatment and autoimmune diseases.

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins

Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins

Lysosome-targeting chimaeras for degradation of extracellular proteins

Effects of leukemia inhibitory factor (LIF) on gene transfer efficiency into murine hematolymphoid progenitors.

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect

Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface

Targeted protein degradation directly engaging lysosomes or proteasomes

Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

An all-in-one targeted protein degradation platform guided by degradation condensates-bridging bi-specific nanobodies

LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation

Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat.

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Recent advances in targeted protein degraders as potential therapeutic agents

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques